iSpecimen Inc. (ISPC)
USD 1.27
(4.1%)
USD 1.27
(4.1%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.14 Million USD | 85.8% |
| 2022 | -15.12 Million USD | 37.81% |
| 2021 | -24.31 Million USD | -301.43% |
| 2020 | 12.07 Million USD | 14.56% |
| 2019 | 10.53 Million USD | 80.5% |
| 2018 | 5.83 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -1.93 Million USD | 9.98% |
| 2024 Q2 | -2.12 Million USD | -9.77% |
| 2023 FY | -2.14 Million USD | 85.8% |
| 2023 Q4 | -2.14 Million USD | 13.66% |
| 2023 Q3 | -2.48 Million USD | -31.15% |
| 2023 Q2 | -1.89 Million USD | 47.54% |
| 2023 Q1 | -3.61 Million USD | 76.09% |
| 2022 Q2 | -20 Million USD | 10.61% |
| 2022 Q4 | -15.12 Million USD | 11.05% |
| 2022 Q1 | -22.37 Million USD | 7.98% |
| 2022 FY | -15.12 Million USD | 37.81% |
| 2022 Q3 | -17 Million USD | 15.0% |
| 2021 Q2 | -10.18 Million USD | -192.11% |
| 2021 FY | -24.31 Million USD | -301.43% |
| 2021 Q1 | 11.05 Million USD | -8.41% |
| 2021 Q4 | -24.31 Million USD | -282.19% |
| 2021 Q3 | -6.36 Million USD | 37.53% |
| 2020 FY | 12.07 Million USD | 14.56% |
| 2020 Q3 | 11.8 Million USD | 0.0% |
| 2020 Q1 | 53.89 Thousand USD | -99.49% |
| 2020 Q4 | 12.07 Million USD | 2.23% |
| 2019 FY | 10.53 Million USD | 80.5% |
| 2019 Q4 | 10.53 Million USD | 0.0% |
| 2018 FY | 5.83 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aspira Women's Health Inc. | -331 Thousand USD | -548.768% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -72.771% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | 60.472% |
| Standard BioTools Inc. | 46.5 Million USD | 104.618% |
| Inotiv, Inc. | 382.14 Million USD | 100.562% |
| Prenetics Global Limited | -43.33 Million USD | 95.045% |
| Neuronetics, Inc. | 2.79 Million USD | 176.776% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 85.998% |
| Castle Biosciences, Inc. | -83.53 Million USD | 97.429% |
| Psychemedics Corporation | 334 Thousand USD | 742.941% |
| RadNet, Inc. | 1.14 Billion USD | 100.187% |
| Exact Sciences Corporation | 1.94 Billion USD | 100.11% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 100.435% |
| OpGen, Inc. | 11.89 Million USD | 118.058% |
| Exagen Inc. | -12.77 Million USD | 83.186% |
| Bionano Genomics, Inc. | 34.88 Million USD | 106.156% |
| CareDx, Inc | -47.97 Million USD | 95.524% |
| Check-Cap Ltd. | -24.75 Million USD | 91.326% |
| Twist Bioscience Corporation | -192.4 Million USD | 98.884% |
| Guardant Health, Inc. | 220.22 Million USD | 100.975% |
| Biodesix, Inc. | 34.3 Million USD | 106.259% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | 62.95% |
| Precipio, Inc. | -386 Thousand USD | -456.327% |
| Natera, Inc. | -200.1 Million USD | 98.927% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 97.399% |
| Sera Prognostics, Inc. | -2.02 Million USD | -6.203% |
| 23andMe Holding Co. | -141.37 Million USD | 98.481% |
| OPKO Health, Inc. | 230.68 Million USD | 100.931% |
| Personalis, Inc. | -8.02 Million USD | 73.231% |
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 94.557% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | 63.689% |
| T2 Biosystems, Inc. | 33.8 Million USD | 106.352% |
| Neogen Corporation | 735.62 Million USD | 100.292% |
| Myriad Genetics, Inc. | 88.1 Million USD | 102.437% |
| ICON Public Limited Company | 3.56 Billion USD | 100.06% |
| NeoGenomics, Inc. | 269.19 Million USD | 100.798% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 85.998% |
| MDxHealth SA | 18.88 Million USD | 111.371% |
| Prenetics Global Limited | -43.33 Million USD | 95.045% |
| Illumina, Inc. | 1.21 Billion USD | 100.177% |
| DarioHealth Corp. | -7.54 Million USD | 71.55% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | 11.973% |
| Medpace Holdings, Inc. | -103.32 Million USD | 97.922% |
| Mainz Biomed B.V. | 349.85 Thousand USD | 713.803% |
| Trinity Biotech plc | 63.73 Million USD | 103.369% |
| Sotera Health Company | 2.02 Billion USD | 100.106% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -72.771% |